Gilead Sciences: Please collaborate with Bristol Myers for the Cure for Hepatitis C NOW!

Sunday, 16 September 2012

Please read and then click here to sign this petition to Gilead Sciences, organised by Margret Dudley via -

"Because patients should be first and foremost. This disease is now killing more then HIV"
Dear Gilead Sciences

Over 170 million Hepatitis C Virus sufferers and their families were ecstatic when you released the data at the past European Association for the Study of the Liver (EASL) conference about the spectacular results achieved with the drug combination of your GS-7977 and Bristol-Myers’ daclatasvir.

It was nothing short of amazing, a 100% cure rate in genotype 1 patients and 91% in genotypes 2 & 3 without the utilization of Interferon or Ribavirin. Our prayers were finally answered, or so it seemed. Then, to our utter dismay and puzzlement, Gilead Sciences elected not to take these drugs into Phase III trials!

If recouping the investment of $11 billion and making profits are at the forefront of Gilead’s considerations, it would seem that expediting these drugs to market would be the paramount concern. If Gilead Sciences is determined to move ahead without Bristol Myers Squibb’s Daclatasvir and elects to pursue drug trials with GS-7977 + Ribavirin (along with its dreadful side effects) or GS-7977 + GS-5885, then it is a shame that the published results of the drug combination of GS-7977 and Bristol-Myers’ Daclatasvir has brought false hopes to over 170 million HCV sufferers and summarily, left us in a state of despair!

What is to be achieved in future trials with other drugs? How can Gilead Sciences abandon a proven drug combination that has 100% cure rate, with minimal side effects (headaches, fatigue, and nausea)? These are results that are going to be hard to top.

It is estimated that currently only 3% of the HCV population elects to undergo treatment because of the dreadful side effects of Interferon & Ribavirin. Please factor into your considerations that nearly 100% of HCV patients would undergo treatment if these drugs were made available.

If Gilead Sciences delays moving ahead with the efficacious GS-7977 and Bristol-Myers’ daclatasvir trial-proven drug combination, how many more people will advance to cirrhosis and/or liver cancer, how many more will require a liver transplant, and how many more lives will be lost?

Click here to sign this petition, Thank you... Ian


Post a Comment

Share it!

Share |

My Diary Posts

My Diary Posts

My Diary Posts

Thanks for calling!

What Is Hepatitis C?

Hepatitis C Information:

Hepatits C is a blood-borne viral disease which can cause liver inflamation, fibrosis, cirrhosis and liver cancer. The Hepatitis C virus (HCV) is spread by blood-to-blood contact with infected person's blood. Many people with HCV infection have no symptoms and are unaware of the need to seek treatment. Hepatitis C infects an estimated 150-200 million people worldwide. It is the leading cause of liver Transplant...

Hepatitis C is an inflamation of the liver caused by infection with the Hepatitis C virus is one of the five known hepatitis viruses: A, B, C, D & E. Hepatitis C was previousley known as non-A non-B hepatitis prior to isolation of the virus in 1989.

Symptoms of Acute Hepatitis C:

Acute Hepatitis C refers to first 6 months after infection with HCV. Remarkably, 60% - 70% of people develop no symptoms during the acute phase. In the minority of patients who experience acute phase symptoms, thet are generally mild and non-specific, and rarely lead to specific diagnoses of Hepatitis C. Symptoms of acute hepatitis C include decreased appetite, fatigue, abdominal pain, jaundice, itching and flu-like symptoms.

Symptoms of Chronic Hepatitis C:

Chronic Hepatitis C is defined as infection with the Hepatitis C virus persisting for more than six months. The course of chronic hepatitis C varies considerably from one person to another. Virtually all people infected with HCV have evidence of inflamation on liver biopsy however, the rate of progression of liver scarring (fibrosis) shows significant inter-individual variability.

  © Blogger template The Beach by 2009

Back to TOP